Variable at ART initiation | All Patients (n = 123) n (%) | Patients with HIV-1 RNA suppressed at 12 months on ART (VL < 1000 copies/mL) (n = 105) n (%) | Immunologic responder at 12 months on ART (CD4 + T cell recovery ≥ 100 cells) (n = 86) n (%) | Patients with immunovirological discordance at 12 months (n = 25) n (%) |
---|---|---|---|---|
Age: median (IQR) years | 33.00 (29.00–39.17) | 33.02 (30.01–39.02) | 32.93 (28.5–38.80) | 33.00 (31.00–39.23) |
< 30 | 31 (25.20) | 25 (23.81) | 23 (26.74) | 4 (16.00) |
30–39 | 65 (52.85) | 58 (55.24) | 46 (53.49) | 15 (60.00) |
≥ 40 | 27 (21.95) | 22 (20.95) | 17 (19.77) | 6 (24.00) |
Education level | ||||
None | 52 (42.28) | 45 (42.86) | 38 (44.19) | 9 (36.00) |
Primary school | 36 (29.27) | 31 (29.52) | 23 (26.74) | 11 (44.) |
Secondary school | 35 (28.45 | 29 (27.62) | 25 (29.07) | 5 (20.00) |
Marital status (couple life) | ||||
Yes | 29 (23.58) | 23 (21.90) | 21 (24.42) | 4 (16.00) |
No | 94 (76.42) | 82 (78.10) | 65 (75.58) | 21 (8400) |
WHO clinical stage | ||||
1 | 17 (13.82) | 13 (12.38) | 12 (13.95) | 3 (12.00) |
2 | 42 (34.15) | 35 (33.33) | 29 (33.72) | 8 (32.00) |
3 and 4 | 64 (52.03) | 57 (54.29) | 45 (52.33) | 14 (56.00) |
Body mass index: median (IQR) | 20.60 (18.55–22.72) | 20.58 (18.13–22.55) | 20.38 (18.24–22.37) | 20.76 (18.55–23.51) |
< 18,5 | 29 (23.58) | 28 (26.67) | 23 (26.74) | 6 (24.00) |
18,5–25 | 83 (67.48) | 67 (63.81) | 57 (66.28) | 15 (60.00) |
> 25 | 11 (8.94) | 10 (9.52) | 6 (6.98) | 4 (16.00) |
CD4 + T cell count at ART initiation: Median (IQR) | 147 (79–200) | 139 (74–200) | 136 (75–192) | 238 (100–384) |
< 200 | 90 (73.17) | 77 (73.33) | 70 (81.40) | 11 (44.00) |
200–349 | 23 (18.70) | 19 (18.10) | 14 (16.28) | 7 (28.00) |
350 -500 | 10 (8.13) | 9 (8.57) | 2 (2.33) | 7 (28.00) |
HIV-1 Viral load (log 10copies/ml): median (IQR) (n = 52) | 5.20 (4.82–5.52) | 5.26 (4.85–5.58) | 5.18 (4.82–5.54) | 5.43 (5.28–5.65) |
< 3 log10 | 2 (3.85) | 2 (4.17) | 2 (4.76) | - |
3–5 log10 | 16 (30.77) | 13 (27.08) | 13 (30.95) | 1 (12.50) |
> 5log10 | 34 (65.38) | 33 (68.75) | 27 (64.29) | 7 (87.50) |
ART NNRTIs initiated | ||||
Nevirapine | 38 (30.89) | 30 (28.57) | 28 (32.56) | 5 (20.00) |
Efavirenz | 83 (67.48) | 73 (69.52) | 56 (65.12) | 20 (80.00) |
Protease inibitor | 2 (1.63) | 2 (1.90) | 2 (2.33) | |
ART NRTIs initiated | ||||
Tenofovir | 18 (14.63) | 15 (14.29) | 11 (12.79) | 6 (24.00) |
Zidovudine | 73 (59.35) | 64 (60.95) | 49 (56.98) | 17 (68.00) |
Stavudine | 32 (26.02) | 26 (24.76) | 26 (30.23) | 2 (8.00) |
ART Adherence: median (IQR) | 97.00 (92.5–99.40 | 97.00 (93.5–99.65) | 97.00 (92.00–99.40) | 96.40 (95.30–100) |
< 95% | 45 (36.59) | 37 (35.24) | 35 (40.70) | 6 (24) |
≥ 95% | 78 (63.41) | 68 (64.76) | 51 (59.30) | 19 (76) |